BACKGROUND: Mechanisms responsible for anti-ischemic benefits of enhanced external counterpulsation (EECP) remain unknown. This was the first randomized sham-controlled study to investigate the extracardiac effects of EECP on peripheral artery flow-mediated dilation. METHODS AND RESULTS:Forty-two symptomatic patients with coronary artery disease were randomized (2:1 ratio) to thirty-five 1-hour sessions of either EECP (n=28) or sham EECP (n=14). Flow-mediated dilation of the brachial and femoral arteries was performed with the use of ultrasound. Plasma levels of nitrate and nitrite, 6-keto-prostaglandin F(1α), endothelin-1, asymmetrical dimethylarginine, tumor necrosis factor-α, monocyte chemoattractant protein-1, soluble vascular cell adhesion molecule, high-sensitivity C-reactive protein, and 8-isoprostane were measured. EECP increased brachial (+51% versus +2%) and femoral (+30% versus +3%) artery flow-mediated dilation, the nitric oxide turnover/production markers nitrate and nitrite (+36% versus +2%), and 6-keto-prostaglandin F(1α) (+71% versus +1%), whereas it decreased endothelin-1 (-25% versus +5%) and the nitric oxide synthase inhibitor asymmetrical dimethylarginine (-28% versus +0.2%) in treatment versus sham groups, respectively (all P<0.05). EECP decreased the proinflammatory cytokines tumor necrosis factor-α (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%), soluble vascular cell adhesion molecule-1 (-6% versus +1%), high-sensitivity C-reactive protein (-32% versus +5%), and the lipid peroxidation marker 8-isoprostane (-21% versus +1.3%) in treatment versus sham groups, respectively (all P<0.05). EECP reduced angina classification (-62% versus 0%; P<0.001) in treatment versus sham groups, respectively. CONCLUSIONS: Our findings provide novel mechanistic evidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and endothelial-derived vasoactive agents in patients with symptomatic coronary artery disease.
RCT Entities:
BACKGROUND: Mechanisms responsible for anti-ischemic benefits of enhanced external counterpulsation (EECP) remain unknown. This was the first randomized sham-controlled study to investigate the extracardiac effects of EECP on peripheral artery flow-mediated dilation. METHODS AND RESULTS: Forty-two symptomatic patients with coronary artery disease were randomized (2:1 ratio) to thirty-five 1-hour sessions of either EECP (n=28) or sham EECP (n=14). Flow-mediated dilation of the brachial and femoral arteries was performed with the use of ultrasound. Plasma levels of nitrate and nitrite, 6-keto-prostaglandin F(1α), endothelin-1, asymmetrical dimethylarginine, tumor necrosis factor-α, monocyte chemoattractant protein-1, soluble vascular cell adhesion molecule, high-sensitivity C-reactive protein, and 8-isoprostane were measured. EECP increased brachial (+51% versus +2%) and femoral (+30% versus +3%) artery flow-mediated dilation, the nitric oxide turnover/production markers nitrate and nitrite (+36% versus +2%), and 6-keto-prostaglandin F(1α) (+71% versus +1%), whereas it decreased endothelin-1 (-25% versus +5%) and the nitric oxide synthase inhibitor asymmetrical dimethylarginine (-28% versus +0.2%) in treatment versus sham groups, respectively (all P<0.05). EECP decreased the proinflammatory cytokines tumor necrosis factor-α (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%), soluble vascular cell adhesion molecule-1 (-6% versus +1%), high-sensitivity C-reactive protein (-32% versus +5%), and the lipid peroxidation marker 8-isoprostane (-21% versus +1.3%) in treatment versus sham groups, respectively (all P<0.05). EECP reduced angina classification (-62% versus 0%; P<0.001) in treatment versus sham groups, respectively. CONCLUSIONS: Our findings provide novel mechanistic evidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and endothelial-derived vasoactive agents in patients with symptomatic coronary artery disease.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: Tomasz P Stys; William E Lawson; John C K Hui; Bruce Fleishman; Karen Manzo; John E Strobeck; Joseph Tartaglia; Subramanian Ramasamy; Raymond Suwita; Zhen Sheng Zheng; Hong Liang; Dierk Werner Journal: Am J Cardiol Date: 2002-04-01 Impact factor: 2.778
Authors: D Masuda; R Nohara; T Hirai; K Kataoka; L G Chen; R Hosokawa; M Inubushi; E Tadamura; M Fujita; S Sasayama Journal: Eur Heart J Date: 2001-08 Impact factor: 29.983
Authors: P Aukrust; R K Berge; T Ueland; E Aaser; J K Damås; L Wikeby; A Brunsvig; F Müller; K Forfang; S S Frøland; L Gullestad Journal: J Am Coll Cardiol Date: 2001-02 Impact factor: 24.094
Authors: Nikolaos Pagonas; Wolfgang Utz; Jeanette Schulz-Menger; Andreas Busjahn; Jan Monti; Ludwig Thierfelder; Rainer Dietz; Volker Klauss; Michael Gross; Ivo R Buschmann; Eva-Elina Buschmann Journal: Int J Cardiol Date: 2009-06-17 Impact factor: 4.164
Authors: Darren P Casey; Darren T Beck; Wilmer W Nichols; C Richard Conti; Calvin Y Choi; Matheen A Khuddus; Randy W Braith Journal: Am J Cardiol Date: 2011-03-17 Impact factor: 2.778
Authors: Bruno T Roseguini; Arturo A Arce-Esquivel; Sean C Newcomer; Hsiao T Yang; Ronald Terjung; M H Laughlin Journal: J Appl Physiol (1985) Date: 2012-02-23
Authors: Darren T Beck; Jeffrey S Martin; Darren P Casey; Joseph C Avery; Paloma D Sardina; Randy W Braith Journal: Clin Exp Pharmacol Physiol Date: 2014-09 Impact factor: 2.557